While the Trump administration has in the past proposed international reference pricing for drug pricing in the U.S., a Health Affairs blog post suggests domestic reference pricing for COVID-19 therapies.
Domestic reference pricing, Sean Dickson and Timothy Lash write, could help drive pricing discussions upon the launch of a new drug.
“For a drug such as remdesivir that treats an emergent condition, we cannot wait to see how other countries will price the treatment,” they write. “For new drugs, and drugs treating COVID-19 in particular, domestic reference pricing offers a touchstone to guide pricing discussions immediately upon a drug’s launch.”
To read the full blog post, click here.